INR 80.89
(0.21%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 676.14 Million INR | 21.69% |
2022 | 555.63 Million INR | -7.36% |
2021 | 599.78 Million INR | 12.69% |
2020 | 532.22 Million INR | 11.9% |
2019 | 475.62 Million INR | 5.95% |
2018 | 448.9 Million INR | -3.2% |
2017 | 463.75 Million INR | 5.96% |
2016 | 437.66 Million INR | 37.07% |
2015 | 319.29 Million INR | 30.02% |
2014 | 245.56 Million INR | 18.94% |
2013 | 206.46 Million INR | 14.92% |
2012 | 179.65 Million INR | -6.46% |
2011 | 192.05 Million INR | 20.25% |
2010 | 159.71 Million INR | 131.51% |
2009 | 68.98 Million INR | 13.01% |
2008 | 61.04 Million INR | 15.44% |
2007 | 52.88 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 183.67 Million INR | -11.59% |
2023 Q1 | 280.24 Million INR | 217.56% |
2023 FY | 676.14 Million INR | 21.69% |
2023 Q4 | 207.75 Million INR | 71.39% |
2023 Q3 | 121.21 Million INR | -62.37% |
2023 Q2 | 322.11 Million INR | 14.94% |
2022 Q3 | 263.74 Million INR | -2.46% |
2022 FY | 555.63 Million INR | -7.36% |
2022 Q4 | -238.39 Million INR | -190.39% |
2022 Q1 | 277.54 Million INR | 518.19% |
2022 Q2 | 270.38 Million INR | -2.58% |
2021 Q2 | 226.69 Million INR | 5.25% |
2021 Q4 | 44.89 Million INR | -70.52% |
2021 Q1 | 215.37 Million INR | 365.9% |
2021 Q3 | 152.29 Million INR | -32.82% |
2021 FY | 599.78 Million INR | 12.69% |
2020 Q1 | 190.54 Million INR | 516.6% |
2020 FY | 532.22 Million INR | 11.9% |
2020 Q3 | 208.22 Million INR | 3.88% |
2020 Q4 | -81 Million INR | -138.9% |
2020 Q2 | 200.45 Million INR | 5.2% |
2019 FY | 475.62 Million INR | 5.95% |
2019 Q1 | 174.36 Million INR | 235.65% |
2019 Q4 | -45.73 Million INR | -126.11% |
2019 Q2 | 171.84 Million INR | -1.44% |
2019 Q3 | 175.14 Million INR | 1.92% |
2018 FY | 448.9 Million INR | -3.2% |
2018 Q4 | -128.53 Million INR | -165.12% |
2018 Q3 | 197.38 Million INR | -1.48% |
2018 Q2 | 200.36 Million INR | 11.5% |
2018 Q1 | 179.69 Million INR | -8.45% |
2017 Q3 | 169.14 Million INR | -7.6% |
2017 Q2 | 183.05 Million INR | -12.28% |
2017 FY | 463.75 Million INR | 5.96% |
2017 Q1 | 208.68 Million INR | 21.62% |
2017 Q4 | 196.28 Million INR | 16.05% |
2016 Q2 | 150.02 Million INR | 6.14% |
2016 Q1 | 141.35 Million INR | 251.89% |
2016 Q4 | 171.58 Million INR | -5.53% |
2016 FY | 437.66 Million INR | 37.07% |
2016 Q3 | 181.63 Million INR | 21.07% |
2015 Q1 | 121.99 Million INR | 361.87% |
2015 Q2 | 142.82 Million INR | 17.07% |
2015 FY | 319.29 Million INR | 30.02% |
2015 Q4 | -93.06 Million INR | -171.11% |
2015 Q3 | 130.87 Million INR | -8.37% |
2014 Q2 | 84.62 Million INR | -14.63% |
2014 Q3 | 108.27 Million INR | 27.95% |
2014 FY | 245.56 Million INR | 18.94% |
2014 Q4 | -46.58 Million INR | -143.03% |
2014 Q1 | 99.12 Million INR | 218.26% |
2013 Q1 | 79.36 Million INR | 286.48% |
2013 Q2 | 98.73 Million INR | 24.41% |
2013 FY | 206.46 Million INR | 14.92% |
2013 Q4 | -83.81 Million INR | -175.71% |
2013 Q3 | 110.7 Million INR | 12.13% |
2012 Q1 | 71.37 Million INR | 175.73% |
2012 FY | 179.65 Million INR | -6.46% |
2012 Q4 | -42.55 Million INR | -147.37% |
2012 Q3 | 89.84 Million INR | 18.21% |
2012 Q2 | 76.01 Million INR | 6.49% |
2011 FY | 192.05 Million INR | 20.25% |
2011 Q4 | -94.25 Million INR | -207.0% |
2011 Q3 | 88.09 Million INR | 0.0% |
2010 FY | 159.71 Million INR | 131.51% |
2009 FY | 68.98 Million INR | 13.01% |
2008 FY | 61.04 Million INR | 15.44% |
2007 FY | 52.88 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bal Pharma Limited | 389.89 Million INR | -73.42% |
Achyut Healthcare Limited | 1.6 Million INR | -41922.809% |
Alkem Laboratories Limited | 32.83 Billion INR | 97.941% |
Divi's Laboratories Limited | 14.17 Billion INR | 95.228% |
Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.999% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 94.192% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -1364.917% |
Mankind Pharma Limited | 23.15 Billion INR | 97.08% |
Medicamen Biotech Limited | 335.16 Million INR | -101.734% |
Medico Remedies Limited | 161.84 Million INR | -317.777% |
Megasoft Limited | 49.52 Million INR | -1265.181% |
Procter & Gamble Health Limited | 2.99 Billion INR | 77.427% |
Piramal Pharma Limited | 19.91 Billion INR | 96.605% |
Sequent Scientific Limited | 2.9 Billion INR | 76.699% |
Sigachi Industries Limited | 579.88 Million INR | -16.6% |
Ajanta Pharma Limited | 30.46 Billion INR | 97.78% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.561% |
Brooks Laboratories Limited | 51.18 Million INR | -1221.116% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 78.007% |
Themis Medicare Limited | 782.85 Million INR | 13.631% |
Unichem Laboratories Limited | 6.72 Billion INR | 89.947% |
Hester Biosciences Limited | 908.84 Million INR | 25.603% |
Venus Remedies Limited | 1.91 Billion INR | 64.716% |
Indoco Remedies Limited | 4.74 Billion INR | 85.762% |
Ind-Swift Limited | 946.56 Million INR | 28.569% |
Aarti Drugs Limited | 1.16 Billion INR | 42.085% |
Alpa Laboratories Limited | 156.14 Million INR | -333.02% |
AstraZeneca Pharma India Limited | 2.6 Billion INR | 73.998% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.295% |
Granules India Limited | 7.18 Billion INR | 90.586% |
Gufic Biosciences Limited | 1.07 Billion INR | 37.261% |
Hikal Limited | 2.48 Billion INR | 72.806% |
RPG Life Sciences Limited | 1.63 Billion INR | 58.658% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 51.8% |
Windlas Biotech Limited | 1 Billion INR | 32.823% |
ZIM Laboratories Limited | 1.01 Billion INR | 33.257% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 68.169% |
IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 38.465% |
Jubilant Pharmova Limited | 14.45 Billion INR | 95.322% |
Aurobindo Pharma Limited | 39.23 Billion INR | 98.277% |
Bajaj HealthCare Limited | 985.34 Million INR | 31.38% |
Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -4071.25% |
Ipca Laboratories Limited | 13.91 Billion INR | 95.141% |
Lasa Supergenerics Limited | 291.17 Million INR | -132.214% |
Laurus Labs Limited | 3.01 Billion INR | 77.543% |
NATCO Pharma Limited | 10.05 Billion INR | 93.278% |
Nectar Lifesciences Limited | 625.55 Million INR | -8.088% |
Shilpa Medicare Limited | 2.18 Billion INR | 68.992% |
Solara Active Pharma Sciences Limited | 4.57 Billion INR | 85.236% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 96.844% |
Wanbury Limited | 1.16 Billion INR | 41.758% |
Wockhardt Limited | 6.4 Billion INR | 89.435% |
Strides Pharma Science Limited | 9.16 Billion INR | 92.62% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 52.358% |
Suven Life Sciences Limited | 109.75 Million INR | -516.079% |
Amrutanjan Health Care Limited | 1.09 Billion INR | 38.475% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 95.739% |
Eris Lifesciences Limited | 4.94 Billion INR | 86.321% |
Lupin Limited | 95.67 Billion INR | 99.293% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 78.024% |
Syncom Formulations (India) Limited | 942.39 Million INR | 28.253% |
Valiant Laboratories Limited | 36.28 Million INR | -1763.229% |
Zydus Lifesciences Limited | 43.17 Billion INR | 98.434% |
FDC Limited | 5.34 Billion INR | 87.358% |
J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 91.967% |
Novartis India Limited | 470.1 Million INR | -43.83% |
Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | 12.576% |
Neuland Laboratories Limited | 2.92 Billion INR | 76.921% |
Morepen Laboratories Limited | 1.98 Billion INR | 65.979% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -63.943% |